Interestingly, catalytic Akt inhibitors (e.g. GDC-0068 and AZD5363) have inhibitory effects in breast tumor cell lines with Akt mutations, whereas allosteric inhibitors (e.g. MK-2206) do not exert inhibitory effect on breast, colon and ovarian cancer cells [12, 13]. The gene discussed is AKT1; the disease is ovarian carcinoma.